A combination of two new-generation cancer drugs modestly delayed the time it took for cancer to worsen in a study of 300 women with very advanced disease who had stopped responding to other treatments. It was the first test of these two highly targeted drugs, Herceptin and Tykerb. Both aim …
Read More »